

# CE-224535

Catalog No: tcsc0006791



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

724424-43-5

**Formula:**

$C_{22}H_{29}ClN_4O_6$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

P2X Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

PF-04905428

**Observed Molecular Weight:**

480.94


## Product Description

CE-224535 is a selective **P2X<sub>7</sub> receptor** antagonist.

IC<sub>50</sub> & Target: P2X<sub>7</sub> receptor<sup>[1]</sup>

**In Vitro:** CE-224535 is developed as a disease-modifying antirheumatic drugs (DMARD) and is a selective antagonist of the human P2X<sub>7</sub> receptor. CE-224535 can reduce leukocyte secretion of IL-1 and IL-18, thereby providing a novel therapeutic approach for treatment of rheumatoid arthritis (RA)<sup>[1]</sup>.

**In Vivo:** In rats, CE-224535 has low CL<sub>p</sub> (11 mL/min/kg) and a large V<sub>dss</sub> of 7.6 L/kg, which results in a half-life of 2.4 h. Upon oral administration to rats at 5 mg/kg, CE-224535 provides maximal plasma exposure (C<sub>max</sub>) that is ~90 fold over its IC<sub>90</sub> in human blood (C<sub>max</sub>=0.21 µg/mL or 0.44 µM). The oral bioavailability of CE-224535 is low in rats (F=2.6%), but this is believed to be a rat specific phenomenon since corresponding oral bioavailability in both dog (59%) and monkey (22%) is adequate<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!